Skip to content

MaxCyte MXCT Interest Income

Interest Income at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$233M+14.8%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$717.17K+377%
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
$256K-45.1%
PDE
Pro-Dex, Inc.PDEX
$53K+253%
Repligen logo
RepligenRGEN
$6.34M-13.3%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO

Other financials

Income statement

See full
Revenue$9.7M-7.1%
Gross profit$8.1M-9.1%
Operating income-$6.2M+49.7%
Net income-$4.8M+53.7%
EPS (diluted)-$0.04+60.0%

Balance sheet

See full
Cash & equivalents$14.6M-37.8%
Total debt$17.5M-7.1%
Total equity$167.9M-15.8%
Total assets$194.5M-15.4%

Cash flow

See full
Operating cash flow-$8.2M+43.3%
CapEx$72.0K-89.0%
Free cash flow-$8.2M+45.3%

Valuation

See full
Market cap$130.15M-46.8%
Enterprise value$133.08M-46.3%
P/S-2.8×

Profitability

See full
Gross margin80.5%-0.4pp
Operating margin-141.8%+6.4pp
Net margin-121.2%+12.3pp
FCF margin-90.9%+3.7pp

Returns & leverage

See full
Return on equity-21.3%+2.0pp
Debt / equity0.1×0.0×
Current ratio12×-0.2×

Where this comes from

Reported directly by MaxCyte in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MaxCyte's interest income?
MaxCyte (MXCT) reported interest income of $1.44M in Q1 2026.
How has MaxCyte's interest income changed year-over-year?
MaxCyte's interest income decreased by 29.4% year-over-year, from $2.03M to $1.44M.
What is the long-term trend for MaxCyte's interest income?
Over 4 years (2021 to 2025), MaxCyte's interest income has grown at a 163.5% compound annual growth rate (CAGR), from $150.7K to $7.27M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.